Keyphrases
Genetic Polymorphism
100%
CYP3A5
100%
Ulcerative Colitis Patient
100%
Cytochrome P450 3A (CYP3A)
100%
Tacrolimus Pharmacokinetics
100%
Tacrolimus
71%
ATP-binding Cassette Transporter A1 (ABCA1)
42%
Adverse Events
42%
Cytochrome P450 3A4 (CYP3A4)
42%
Concentration-dose Ratio
42%
Nuclear Receptor Related Factor 1
42%
CYP3A4*1G
42%
Subfamily C
42%
Genotype
28%
Polymorphism
28%
Gene Polymorphism
28%
Ulcerative Colitis
28%
CYP2C19
28%
Refractory Ulcerative Colitis
28%
Metabolism
14%
Therapeutic Effect
14%
Moderate to Severe
14%
C(T)
14%
Clinical Effect
14%
Inducer
14%
Remission
14%
Inter-individual Variability
14%
Pharmacokinetic Effects
14%
Genotype P
14%
Biochemistry, Genetics and Molecular Biology
Pharmacokinetics
100%
Genetic Polymorphism
100%
CYP3A
100%
CYP3A5
100%
CYP3A4
85%
Genotyping
57%
Allele
42%
Adenosine Triphosphate
42%
Nuclear Receptor
42%
Dose Ratio
42%
Gene Polymorphism
28%
CYP2C19
28%
Metabolic Pathway
14%
Pharmacology, Toxicology and Pharmaceutical Science
Tacrolimus
100%
Ulcerative Colitis
100%
CYP3A
100%
Pharmacokinetics
100%
Cytochrome P450 3A5
87%
CYP3A4
75%
Adverse Event
37%
Cell Nucleus Receptor
37%
Multidrug Resistance Associated Protein
37%
Dose Concentration
37%
Therapeutic Effect
25%
CYP2C19
25%
Remission
12%
Immunology and Microbiology
Tacrolimus
100%
Pharmacokinetics
100%
Ulcerative Colitis
100%
Genetic Polymorphism
100%
Allele
37%
Dose Ratio
37%
DNA Polymorphism
25%